Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ib/II study of QLF31907 (PD-L1/4-1BB bispecific antibody) in advanced malignant tumors
CTR20241445Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QLF31907 in Non-hematologic malignancy, sponsored by Qilu Pharmaceutical. Started Jul 2024; status: active.
02
Drugs
QLF31907
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on CTR20241445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241445.